Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rolipram. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 19/20 | 1.00 |
| ▸ | PDE4B known ✓ | Q07343 | 12/20 | 1.00 |
| ▸ | PDE4C known ✓ | Q08493 | 11/20 | 1.00 |
| ▸ | PDE4D known ✓ | Q08499 | 11/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | VEGFA | P15692 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | CREBBP | Q92793 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | PDE5A | O76074 | 1/20 | 1.00 |
| ▸ | TNF | P01375 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PDE1A | P54750 | 1/20 | 1.00 |
| ▸ | PDE1B | Q01064 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| S-Rolipram SCHEMBL5321568 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Rolipram SCHEMBL29360376 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| (-)-Rolipram SCHEMBL29598924 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| S-Rolipram SCHEMBL29475409 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| (-)-Rolipram SCHEMBL576805 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Rolipram SCHEMBL3719855 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL3544304 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Rolipram SCHEMBL28973411 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Rolipram SCHEMBL15208132 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL3554826 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 21171 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-3244930-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIV SOUTHERN CALIFORNIA (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4704983-A2 | TREATMENT OF MEMORY LOSS WITH PHOSPHODIESTERASE INHIBITORS | Cyrano Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260041690-A1 | Treatment of Memory Loss with Phosphodiesterase Inhibitors | CYRANO THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | claimed |
| EP-4058037-B1 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | SPINALCYTE LLC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4656641-A2 | METHODS AND DEVICES FOR USING ISOPERILLYL ALCOHOL | University of Southern California (US) | 2025-12-03 | — | — | EP | claimed |
| US-12480096-B2 | Clinical gene signature-based human cell culture model and uses thereof | UNIVERSITE DE STRASBOURG (FR) | 2025-11-25 | — | — | US | claimed |
| EP-4197318-B1 | PHOSPHODIESTERASES INHIBITORS TO PROMOTE IN VITRO PLANT CELL REPROGRAMMING TOWARDS PLANT EMBRYOGENESIS OR MICROCALLUS FORMATION | UNIV FREIBURG ALBERT LUDWIGS (DE) | 2025-11-19 | — | — | EP | claimed |
| EP-4647069-A1 | DRUGS AND COMPOSITIONS FOR USE IN THE TREATMENT OF RETT SYNDROME | UNIVERSITA' DEGLI STUDI DI TRIESTE (IT) | 2025-11-12 | — | — | EP | claimed |
| WO-1992002220-A1 | TNF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-02-20 | — | — | WO | claimed |
| US-5079253-A | COMPOSITION FOR THE TOPICAL TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION | PHARMACIA AB (SE) | 1992-01-07 | — | — | US | claimed |
| EP-0460143-A1 | ROLIPRAM-CONTAINING COMPOSITION FOR TRANSDERMAL APPLICATION. | SCHERING AG (DE) | 1991-12-11 | — | — | EP | claimed |
| EP-0274498-B1 | MEDICAMENTS WITH DELAYED RELEASE OF ACTIVE INGREDIENT | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-09-11 | — | — | EP | claimed |
| WO-1991009634-A1 | ROLIPRAM-CONTAINING COMPOSITION FOR TRANSDERMAL APPLICATION | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1991-07-11 | — | — | WO | claimed |
| EP-0432856-A2 | Use of rolipram in the treatment of dementia | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-06-19 | — | — | EP | claimed |
| EP-0274498-A1 | MEDICAMENTS WITH DELAYED RELEASE OF ACTIVE INGREDIENT. | SCHERING AG (DE) | 1988-07-20 | — | — | EP | claimed |
| WO-1988000046-A1 | MEDICAMENTS WITH DELAYED RELEASE OF ACTIVE INGREDIENT | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1988-01-14 | — | — | WO | claimed |
| US-4193926-A | 4-(Polyalkoxy phenyl)-2-pyrrolidones | SCHERING AKTIENGESELLSCHAFT (DE) | 1980-03-18 | — | — | US | claimed |
| US-4012495-A | USED IN TREATING NEUROLOGICAL AND PSYCHIC DISORDERS | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-03-15 | — | — | US | claimed |